In accordance with the provisions of the executive order, FDA assessed the costs and benefits of regulatory alternatives and appears to have selected the approach that maximizes net benefits while still meeting agency objectives.
The FDA's assessment of the costs and benefits of regulatory alternatives have led to the proposition of an approach that neglects to maximize net benefits.